Upregulated miR-193a-3p as an oncogene in esophageal squamous cell carcinoma regulating cellular proliferation, migration and apoptosis

  • Authors:
    • Yunfeng Yi
    • Jianming Chen
    • Changjie Jiao
    • Jing Zhong
    • Zhiming Song
    • Xiaoping Yu
    • Xiujuan Lu
    • Baoli Lin
  • View Affiliations

  • Published online on: October 5, 2016     https://doi.org/10.3892/ol.2016.5229
  • Pages: 4779-4784
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs (miRs) are small endogenous non‑coding RNAs that play a vital role in carcinogenesis. miR‑193a‑3p has been described in multiple cancers. However, the function of miR‑193a‑3p in esophageal squamous cell carcinoma (ESCC) is still unclear. To explore the role of miR‑193a‑3p in ESCC, reverse transcription‑quantitative polymerase chain reaction was used to evaluate the expression of miR‑193a‑3p in 48 paired ESCC and adjacent normal tissues. In addition, the impact of miR-193a-3p on cell proliferation, migration and apoptosis were analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, wound scratch assay and flow cytometry, respectively. The results revealed that miR‑193a‑3p was upregulated in ESCC, compared with adjacent normal tissues. Downregulation of miR‑193a‑3p expression using a synthesized inhibitor suppressed cell proliferation and migration, and induced cell apoptosis, indicating that miR‑193a‑3p could be characterized as an oncogene in ESCC. In summary, the present study demonstrated that miR‑193a‑3p was upregulated in ESCC, where it plays a significant role by affecting cellular proliferation, migration and apoptosis.

Introduction

Esophageal carcinoma is the fifth and eighth most common cause of mortality worldwide in men and women, respectively (1). In Eastern Asia, esophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal carcinoma, with >100 cases/100,000 population reported annually (2). ESCC is also the major histological type in Chinese populations, resulting in 150,000 mortalities annually (3). Despite the availability of multiple treatments for ESCC, surgical resection remains the primary choice for non-metastatic cases (4). However, even upon curative surgery, the 5-year survival rate for ESCC patients is only 26.2–49.4%, due to local or distant recurrences (5). Therefore, it is critical to identify novel molecular mechanisms to elucidate ESCC oncogenesis and metastasis.

MicroRNAs (miRs) are small endogenous non-coding RNAs that play vital roles in various biological processes (6,7). Mature microRNAs usually bind to 3′-untranslated regions (3′-UTRs) of target genes, leading to messenger RNA degradation or repression of translation, thus downregulating the expression of target genes at post-transcriptional levels (6,8). Since the first microRNA (microRNA-lin-4) was identified in 1993, an increasing number of microRNAs have been reported to be involved in numerous physiological and pathological processes, including carcinogenesis (9,10). Several microRNAs, including miR-21, miR-34a and miR-155, have been observed to be associated with carcinogenesis by targeting oncogenes or anti-oncogenes (1113).

In the present study, the expression of miR-193a-3p was examined in ESCC specimens, and the function of miR-193a-3p in ESCC cells was investigated via cell migration, proliferation and apoptosis assays. The results revealed that miR-193a-3p was upregulated in ESCC tissues and functioned as an oncogene in ESCC by affecting cellular migration, proliferation and apoptosis.

Materials and methods

ESCC tissue samples collection

All ESCC tissues and adjacent normal tissues used in the present study were collected from Dongnan Affiliated Hospital of Xiamen University (Zhangzhou, China) between February, 2013 and December, 2014. Written informed consent was obtained from all patients. The collection and use of these samples was approved by the Ethics Committee of Dongnan Affiliated Hospital of Xiamen University. Fresh ESCC and adjacent normal tissues were immersed in RNAlater (Qiagen GmbH, Hilden, Germany) in 30 min following resection, and subsequently stored at −80°C.

RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

According to the manufacturer's protocol, total RNA was extracted with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and purified with RNeasy Maxi kit (Qiagen GmbH). Total RNA (1 µg of each sample) was used for RT using miScript RT kit (Qiagen GmbH) to obtain the complementary DNA (cDNA) templates. qPCR reaction of miR-193a-3p was performed in an ABI PRISM® 7000 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) using miScript SYBR Green PCR kit (Qiagen GmbH). U6 was used as an endogenous control. The 20 µl reaction mixture contained 2X QuantiTect SYBR Green PCR Master mix (10 µl), 10X miScript Universal Primer (2 µl), specific microRNA primer (0.4 µl), cDNA template (1 µl) and RNase-free water. The forward primer of miR-193a-3p was 5′-AACTGGCCTACAAAGTCCCAGT-3′ and the reverse primer was provided in the miScript SYBR Green PCR kit. The forward primer and reverse primers of U6 were 5′-CTCGCTTCGGCAGCACA-3′ and 5′-ACGCTTCACGAATTTGCGT-3′, respectively. Amplification conditions were set as: 95°C for 2 min, followed by 40 cycles of 94°C for 15 sec, 58°C for 30 sec and 72°C for 30 sec.

Cell culture and transfection

The human ESCC cell lines Eca109 and TE-1 used in the present study were purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China), and were cultured in RPMI 1640 (Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 g/ml streptomycin at 37°C in a humidified incubator containing 5% CO2. For the downregulation of miR-193a-3p expression, a synthesized miR-193a-3p inhibitor (Shanghai GenePharma Co., Ltd., Shanghai, China) was transfected into the cells using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The transfection efficiency and changes in miR-193a-3p expression were determined by fluorescence microscopy and RT-qPCR, respectively.

Migration assay

The migratory ability of ESCC cells (Eca109 and TE-1) in vitro was assessed by wound scratch assay. Approximately 150,000 cells were seeded in a 12-well dish and were transfected with miR-193a-3p inhibitor (60 pmol) or negative control (60 pmol) with Lipofectamine 2000 24 h later. After 5 h of transfection, a vertical wound was created with the tip of a sterile 10-µl pipette, and markers were assigned to enable the observation of cells in the correct location. The cells were then rinsed three times with phosphate-buffered saline (PBS) and incubated at 37°C. Images of the wound scratches were captured with a digital camera system at 0 and 24 h after the wounds were made at the same location. Wound widths (µm) were measured with a standard caliper, and the experiments were performed in triplicate and analyzed by at least two observers.

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

Cell proliferation of ESCC lines (Eca109 and TE-1) was assessed with an MTT assay kit (Sigma-Aldrich, St. Louis, MO, USA). Approximately 5,000 cells were seeded into 96-well plates and transfected with 5 pmol of miR-193a-3p inhibitor or negative control. Next, 20 µl of MTT (5 mg/ml; Sigma-Aldrich) was added to the culture medium of each well at 0, 24, 48 and 72 h post-transfection. After incubation for 4 h, the MTT medium was removed, and 150 µl of dimethyl sulfoxide was added. After shaking for 15 min at room temperature, the optical density (OD) of each sample was assessed with an enzyme-linked immunosorbent assay instrument (model 680; Bio-Rad Rad Laboratories, Inc., Hercules, CA, USA) at a wavelength of 490/630 nm.

Flow cytometry

For apoptosis assay, ESCC cells (Eca109 and TE-1) were cultured in 6-well plates at 37°C and transfected with miR-193a-3p inhibitor or negative control at a confluence of ~65%. After 48 h of transfection, cells were harvested and washed twice with cold PBS, resuspended in 10 µl 1X binding buffer (Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, 5 µl of Annexin V-fluorescein isothiocyanate (Invitrogen; Thermo Fisher Scientific, Inc.) and 10 µl of propidium iodide were added to each sample. The fluorescence of the stained cells was then analyzed by flow cytometry (Beckman Coulter, Inc., Brea, CA, USA) using an excitation wavelength of 488 nm within 30 min of staining, according to the manufacturer's protocol.

Statistical analysis

Statistical analysis was conducted with SPSS 17.0 statistical software package (SPSS, Inc., Chicago, IL, USA). Statistical significance was determined with paired t-test and Student's t test. P<0.05 was considered to indicate a statistically significant difference.

Results

Upregulation of miR-193a-3p in 36 paired ESCC tissues and adjacent normal tissues by RT-qPCR

RT-qPCR was used to determine the expression of miR-193a-3p in 36 paired ESCC tissues and adjacent normal tissues. The relative expression of miR-193a-3p is represented in Fig. 1A. As shown in Fig. 1B, the miR-193a-3p expression in ESCC tissues was significantly higher than that in adjacent normal tissues (P=0.0153).

Transfection and inhibition efficiency

To determine the function of miR-193a-3p in ESCC, miR-193a-3p inhibitor and negative control were transfected into the ESCC cell lines Eca109 and TE-1. Images of the cells transfected with fluorescein amidite-labeled negative control were obtained at 6 h post-transfection, and revealed that the transfection efficiency was ~85 and 80% in Eca109 and TE-1 cells, respectively (Fig. 2A). Compared with the negative control, the relative expression of miR-193a-3p in Eca109 and TE-1 cells transfected with miR-193a-3p inhibitor was 5.5 and 7.3%, respectively (Fig. 2B). These results suggested that the miR-193a-3p inhibitor used in the present study was able to effectively downregulate the expression of miR-193a-3p.

Downregulation of miR-193a-3p suppresses ESCC cell migration in vitro

Wound scratch assay was performed to determine the effects of miR-193a-3p on ESCC cell migration in vitro. Compared with the negative control group, the wound widths of Eca109 and TE-1 cells transfected with miR-193a-3p inhibitor were significantly wider (P=0.0322 and 0.0306, respectively; Fig. 3), which indicated that downregulation of miR-193a-3p inhibited the migration of ESCC cells (Fig. 3).

Reduction of miR-193a-3p inhibits cell proliferation

The impact of miR-193a-3p on cell proliferation in ESCC was analyzed by MTT assay. The OD values of miR-193a-3p inhibitor group and negative control group were measured at 0, 24, 48 and 72 h post-transfection. The results indicated that the proliferation of Eca109 cells decreased by 6.45% (P=0.0318), 10.63% (P=0.0131) and 14.19% (P=0.0019), while the proliferation of TE-1 cells decreased by 6.78% (P=0.0356), 11.51% (P=0.0152) and 14.72% (P=0.0025), at 24, 48 and 72 h post-transfection, respectively (Fig. 4). This indicated that downregulation of miR-193a-3p suppressed the proliferation of ESCC cells in vitro.

Inhibition of miR-193a-3p promotes ESCC cell apoptosis

To determine the function of miR-193a-3p on ESCC cell apoptosis, flow cytometry was performed to detect the apoptosis rates upon transfection. As represented in Fig. 5, the apoptosis rates of Eca109 cells transfected with miR-193a-3p inhibitor and negative control were 7.2 and 2.7% (P=0.0121), respectively, following transfection for 48 h. The apoptosis rates of TE-1 cells were 6.6 and 2.8% (P=0.0154) upon transfection with miR-193a-3p inhibitor and negative control, respectively. These results demonstrated that inhibition of miR-193a-3p induced ESCC cell apoptosis.

Discussion

Carcinogenesis involves the activation of a number of oncogenes and the inactivation of a number of anti-oncogenes (14). In the complicated regulatory network of oncogenes and anti-oncogenes, microRNAs plays a vital role by controlling the expression of target genes at post-transcriptional levels (15). By regulating the levels of oncogenes or anti-oncogenes, a microRNA can act as an anti-oncogene or as an oncogene (8). Although only accounting for a small fraction of the expressed genome, microRNAs play crucial roles in diverse cellular processes, including cell proliferation, cellular differentiation, cell death, metabolism, apoptosis, motility, invasion and morphogenesis (6,10,1620). A number of microRNAs were observed to be upregulated in ESCC, including miR-21 (2123), miR-205 (24), miR-10b (25), miR-23a (26), miR-26a (26), miR-27b (26), miR-96 (26), miR-128b (26), miR-129 (26), miR-93 (23), miR-192 (23) and miR-194 (23). In addition, downregulation of miR-375 (21), miR-203 (23), miR-205 (23), miR-27b (23), miR-125b (23) and miR-100 (23) expression has been detected in ESCC. Furthermore, numerous microRNAs were noticed to play the role of oncogene or anti-oncogene in ESCC, including miR-21, which facilitates ESCC growth by targeting phosphatase and tensin homolog and programmed cell death 4 (22,27); miR-296, which contributes to ESCC growth by targeting cyclin D1 and p27 (28); miR-210, which targets fibroblast growth factor receptor-like 1, thus exerting a negative effect on cell cycle and proliferation (29); miR-145, miR-133a and miR-133b, which converge to target fascin 1, thus reducing cell growth and invasion (30); and miR-593, which may contribute to carcinogenesis through polo-like kinase 1 (31).

miR-193a-3p can function as a tumor suppressor, since it inhibits cell-cycle progression and proliferation in breast cancer through targeting epidermal growth factor receptor-driven cell-cycle network proteins (32) and induces apoptosis in both U-251 and HeLa cells (33). In addition, miR-193a-3p suppresses the metastasis of human non-small-cell lung cancer (34,35). However, the expression and role of miR-193a-3p in ESCC remains unclear.

To determine the expression and role of miR-193a-3p in ESCC, RT-qPCR was used in the present study to quantify the miR-193a-3p level in 36 cases of ESCC tissues and paired normal tissues. The present study demonstrated that miR-193a-3p expression was significantly upregulated in ESCC tissues, compared with its expression levels in paired normal esophageal tissues. The effects of miR-193a-3p on ESCC cell migration, proliferation and apoptosis were then analyzed by transfection of ESCC cell lines with a synthetic miR-193a-3p inhibitor. Transfection of miR-193a-3p inhibitor into the ESCC cell lines Eca109 and TE-1 inhibited cellular proliferation and migration and induced apoptosis, compared with the negative control group. These findings suggested that miR-193a-3p may act as a oncogene in ESCC by inhibiting cellular proliferation and migration and by promoting cellular apoptosis. Further studies on miR-193a-3p target genes are required to clarify the mechanism of action of miR-193a-3p in ESCC.

The role of miR-193a-3p in different cancers appears to be controversial, as it was identified as a tumor suppressor in certain cancers (3235) and as an oncogene in ESCC, according to the results of the present study. Regardless of experimental error, this contradiction may be explained as ‘imperfect’ complementary interactions between microRNAs and their target genes. Contrary to small interfering RNA, the interactions between microRNAs and the 3′-UTRs of their target genes are not always perfectly complementary (particularly in mammals), which leads to relative rather than complete specificity between microRNAs and their target genes (36). Accurate interactions between microRNAs and their target genes may be further dictated by cell types and the microenvironment, thus contributing to the divergent regulatory roles of certain microRNAs (6,37).

In conclusion, the present study revealed that miR-193a-3p was upregulated in ESCC and played a vital oncogenic role in ESCC by affecting cellular migration, proliferation and apoptosis. Further studies are required to define its mechanism of action in ESCC.

References

1 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Zhao P, Dai M, Chen W and Li N: Cancer trends in China. Jpn J Clin Oncol. 40:281–285. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Han LH, Jia YB, Song QX, Wang JB, Wang NN and Cheng YF: Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 16:2245–2250. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Liu J, Xie X, Zhou C, Peng S, Rao D and Fu J: Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg. 41:e7–e11. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A, Wang A, Dai Y and Zhou X: MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J. 432:199–205. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Soeda S, Ohyashiki JH, Ohtsuki K, Umezu T, Setoguchi Y and Ohyashiki K: Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease. Int J Mol Med. 31:533–539. 2013.PubMed/NCBI

8 

Xiong Y, Zhang L, Holloway AK, Wu X, Su L and Kebebew E: MiR-886-3p regulates cell proliferation and migration and is dysregulated in familial non-medullary thyroid cancer. PLoS One. 6:e247172011. View Article : Google Scholar : PubMed/NCBI

9 

Ha TY: MicroRNAs in Human Diseases: From cancer to Cardiovascular Disease. Immune Netw. 11:135–154. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Zhai Q, Zhou L, Zhao C, Wan J, Yu Z, Guo X, Qin J, Chen J and Lu R: Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun. 419:621–626. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Shibuya H, Iinuma H, Shimada R, Horiuchi A and Watanabe T: Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 79:313–320. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Akao Y, Noguchi S, Iio A, Kojima K, Takagi T and Naoe T: Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 300:197–204. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S and Croce CM: Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA. 108:4908–4913. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H and Han J: Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell. 120:623–634. 2005. View Article : Google Scholar : PubMed/NCBI

16 

Bhattacharyya S, Balakathiresan NS, Dalgard C, Gutti U, Armistead D, Jozwik C, Srivastava M, Pollard HB and Biswas R: Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem. 286:11604–11615. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Lucotti S, Rainaldi G, Evangelista M and Rizzo M: Fludarabine treatment favors the retention of miR-485-3p by prostate cancer cells: Implications for survival. Mol Cancer. 12:522013. View Article : Google Scholar : PubMed/NCBI

18 

Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM, et al: Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer. 9:4012009. View Article : Google Scholar : PubMed/NCBI

19 

Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI

20 

Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H and Zhou X: MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics. 6:131–139. 2009.PubMed/NCBI

21 

Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, et al: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin Cancer Res. 15:6192–6200. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M and Baba H: MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res. 15:1915–1922. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, Swanson SJ, Godfrey TE and Litle VR: MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 135:255–260; discussion 260. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Matsushima K, Isomoto H, Kohno S and Nakao K: MicroRNAs and esophageal squamous cell carcinoma. Digestion. 82:138–144. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H and Liu Z: MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem. 285:7986–7994. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, Harata K, Tanaka T and Fujii Y: Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol. 42:102–109. 2009. View Article : Google Scholar : PubMed/NCBI

27 

Ma WJ, Lv GD, Tuersun A, Liu Q, Liu H, Zheng ST, Huang CG, Feng JG, Wang X, Lin RY, et al: Role of microRNA-21 and effect on PTEN in Kazakh's esophageal squamous cell carcinoma. Mol Biol Rep. 38:3253–3260. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Hong L, Han Y, Zhang H, Li M, Gong T, Sun L, Wu K, Zhao Q and Fan D: The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 251:1056–1063. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K and Tsujimoto G: MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 286:420–428. 2010. View Article : Google Scholar : PubMed/NCBI

30 

Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 127:2804–2814. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Ito T, Sato F, Kan T, Cheng Y, David S, Agarwal R, Paun BC, Jin Z, Olaru AV, Hamilton JP, et al: Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer. Int J Cancer. 129:2134–2146. 2011. View Article : Google Scholar : PubMed/NCBI

32 

Uhlmann S, Mannsperger H, Zhang JD, Horvat EÁ, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, et al: Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol. 8:5702012. View Article : Google Scholar : PubMed/NCBI

33 

Kwon JE, Kim BY, Kwak SY, Bae IH and Han YH: Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1. Apoptosis. 18:896–909. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, et al: MicroRNA-193a-3p and −5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene. 34:413–423. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Deng W, Yan M, Yu T, Ge H, Lin H, Li J, Liu Y, Geng Q, Zhu M, Liu L, et al: Quantitative Proteomic analysis of the metastasis-inhibitory mechanism of miR-193a-3p in non-small cell lung cancer. Cell Physiol Biochem. 35:1677–1688. 2015. View Article : Google Scholar : PubMed/NCBI

36 

Kim VN: MicroRNA biogenesis: Coordinated cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385. 2005. View Article : Google Scholar : PubMed/NCBI

37 

Kharaziha P, Ceder S, Li Q and Panaretakis T: Tumor cell-derived exosomes: A message in a bottle. Biochim Biophys Acta. 1826:103–111. 2012.PubMed/NCBI

Related Articles

Journal Cover

December-2016
Volume 12 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yi Y, Chen J, Jiao C, Zhong J, Song Z, Yu X, Lu X and Lin B: Upregulated miR-193a-3p as an oncogene in esophageal squamous cell carcinoma regulating cellular proliferation, migration and apoptosis. Oncol Lett 12: 4779-4784, 2016
APA
Yi, Y., Chen, J., Jiao, C., Zhong, J., Song, Z., Yu, X. ... Lin, B. (2016). Upregulated miR-193a-3p as an oncogene in esophageal squamous cell carcinoma regulating cellular proliferation, migration and apoptosis. Oncology Letters, 12, 4779-4784. https://doi.org/10.3892/ol.2016.5229
MLA
Yi, Y., Chen, J., Jiao, C., Zhong, J., Song, Z., Yu, X., Lu, X., Lin, B."Upregulated miR-193a-3p as an oncogene in esophageal squamous cell carcinoma regulating cellular proliferation, migration and apoptosis". Oncology Letters 12.6 (2016): 4779-4784.
Chicago
Yi, Y., Chen, J., Jiao, C., Zhong, J., Song, Z., Yu, X., Lu, X., Lin, B."Upregulated miR-193a-3p as an oncogene in esophageal squamous cell carcinoma regulating cellular proliferation, migration and apoptosis". Oncology Letters 12, no. 6 (2016): 4779-4784. https://doi.org/10.3892/ol.2016.5229